AACP
ZYME icon

Advantage Alpha Capital Partners’s Zymeworks ZYME Stock Holding History

Advantage Alpha Capital Partners’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-92,307
Closed -$969K – 166
2024
Q1 		$969K Sell
92,307
-44,512
-33% -$494K 0.18% 103
2023
Q4 		$1.42M Buy
+136,819
New +$1.09M 0.27% 91

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Advantage Alpha Capital Partners's ZYME Position: Q2 2024 in Review

Advantage Alpha Capital Partners sold out of Zymeworks (ZYME) in Q2 2024, closing a stake of 92,307 shares — an estimated $969K sold.

Advantage Alpha Capital Partners first reported a position in ZYME in Q4 2023 and held it in 2 quarters. The position peaked at $1.42M in Q4 2023. 164 funds tracked by Wall St. Rank hold ZYME as of Q2 2024.

  • Advantage Alpha Capital Partners reported no remaining Zymeworks position as of Q2 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 92,307 Zymeworks shares in Q2 2024, an estimated $969K.
  • Advantage Alpha Capital Partners first reported a position in Zymeworks in Q4 2023 and held it in 2 quarters.
  • Advantage Alpha Capital Partners's Zymeworks position peaked at $1.42M in Q4 2023.
  • 164 funds tracked by Wall St. Rank held Zymeworks as of Q2 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q2 2024, filed 13 Aug 2024.